Feigenbaum–Bergeron–Richardson Syndrome (FBR Syndrome)

Feigenbaum–Bergeron–Richardson syndrome is an ultra-rare genetic disorder reported in the medical literature in 1994 in two brothers. It combines premature, diffuse atherosclerosis (hardening and narrowing of large and medium arteries), sensorineural deafness, diabetes mellitus, photomyoclonic epilepsy (light-triggered jerks/seizures), progressive neurologic decline with cerebellar signs, and progressive kidney disease (nephropathy). No further patients have been definitively reported since that first family. Some laboratory work from the report and later summaries suggested partial mitochondrial respiratory chain deficiencies (complex III and IV) in kidney/fibroblasts, hinting at a mitochondrial bioenergetic problem, but the exact gene is still unknown. Prognosis in the original report was poor, with deaths in early to mid-adulthood. NCBI+3Genetic & Rare Diseases Center+3Genetic & Rare Diseases Center+3

It is an extremely rare, likely genetic condition reported in two brothers in 1994. These brothers developed premature, severe hardening of the arteries (atherosclerosis), hearing loss, diabetes, epilepsy with photomyoclonus (light-triggered jerks/seizures), progressive neurologic decline, and kidney disease (nephropathy), and died in early adulthood. Because there have been no new cases since 1994, almost everything we know comes from that single report and a few summaries. PubMed+2Orpha+2

Key points in simple terms:

• It seems to be inherited (autosomal or X-linked recessive was suspected), but the exact gene is unknown. PubMed+1

• Autopsy and tissue studies suggested a mitochondrial respiratory chain problem (partial deficiency of complexes III and IV) in kidney cells and fibroblasts, which could explain the multi-organ damage. NCBI

• Frequency: Extremely rare; only the original family is known. Orpha+1

---

Other names

Doctors and databases have used several long descriptive names. All refer to the same clinical picture:

• Atherosclerosis-deafness-diabetes-epilepsy-nephropathy syndrome

• Premature atherosclerosis with photomyoclonic epilepsy, deafness, diabetes mellitus, nephropathy, and neurodegenerative disorder

• Atherosclerosis, premature, with deafness, nephropathy, diabetes mellitus, photomyoclonus, and degenerative neurologic disease Wikipedia+1

The syndrome looks like a whole-body energy problem hitting tissues that need lots of energy (brain, nerves, kidneys), together with striking early artery damage. The original reports and summaries point to mitochondrial dysfunction—the tiny “power plants” inside cells didn’t run parts of the respiratory chain (complexes III and IV) quite right in some tissues. Faulty energy production can increase oxidative stress, damage vessel walls, and worsen insulin handling, which together can speed up atherosclerosis, harm kidneys, and trigger seizures and movement problems. Because only two patients were described, this model is hypothesis-level, not proven. NCBI+1

---

Types

There are no official subtypes because only one family was reported. It can help to think in clinical domains rather than formal types:

1. Vascular-dominant features: early, diffuse atherosclerosis (aorta, renal, coronary, cerebral arteries). Orpha

2. Neuro-dominant features: photomyoclonic epilepsy, progressive neurologic decline, cerebellar symptoms. PubMed+1

3. Metabolic/renal features: diabetes mellitus and progressive nephropathy. PubMed

4. Sensory features: bilateral sensorineural deafness. PubMed

These “domains” are just a practical way to understand the condition; they are not separate types.

---

Causes

Important: The root cause gene is unknown. Below are plausible mechanisms/modifiers drawn from the original cases and rare-disease databases. They explain why the features might occur, but they are not proven primary causes.

1. Inherited defect with recessive pattern (autosomal or X-linked): The two affected brothers and unaffected parents/sisters suggested a recessive inheritance. PubMed

2. Mitochondrial respiratory chain dysfunction (complex III/IV partial deficiency in kidney/fibroblasts): Energy failure can hurt high-demand tissues. NCBI

3. Systemic oxidative stress from mitochondrial inefficiency: Reactive oxygen species can injure vessel lining and accelerate atherosclerosis; this is a biologic inference compatible with the tissue findings. NCBI

4. Endothelial dysfunction: Damaged vessel lining promotes plaque formation and organ ischemia, aligning with diffuse early atherosclerosis. (Mechanistic inference anchored to reported vascular burden.) Orpha

5. Insulin-secretory or insulin-action stress: Mitochondrial stress can impair beta-cells and glucose handling, contributing to diabetes. (Mechanistic inference; diabetes was present.) PubMed

6. Neuronal hyperexcitability (photomyoclonus): Altered energy metabolism and ion handling can lower seizure thresholds, especially with light triggers. (Phenotype reported; mechanism inferred.) PubMed

7. Cerebellar involvement: Explains coordination problems; consistent with “progressive neurologic deterioration with cerebellar symptoms.” NCBI

8. Renal microvascular atherosclerosis/arteriolosclerosis: Fits the progressive nephropathy with vascular pathology at autopsy. PubMed

9. Lipid handling disturbances secondary to mitochondrial dysfunction: Can amplify plaque formation. (Biologic inference given severe early atherosclerosis.) Orpha

10. Hypertension as a downstream amplifier: Frequently travels with kidney disease and atherosclerosis, worsening both. (Hypertension listed among symptoms in secondary sources.) checkorphan.org

11. Genetic background/consanguinity risk: Recessive conditions are more likely in consanguineous families (general genetics principle; specific family history not reported). (Contextual inference.) Orpha

12. Tissue-specific mitochondrial vulnerability: Complex deficiencies noted in kidney/fibroblasts but not muscle, suggesting tissue selectivity. NCBI

13. Energy-dependent auditory pathway injury: Sensorineural deafness is common in mitochondrial disorders. (Phenotype here; mechanism inferred.) PubMed

14. Cerebral small- and large-vessel disease: Early brain vessel atherosclerosis can worsen seizures and cognition. (Inference consistent with “diffuse” atherosclerosis.) Orpha

15. Pro-inflammatory milieu from metabolic stress: Chronic inflammation drives plaques and end-organ injury. (General mechanism consistent with phenotype.) Orpha

16. Autonomic imbalance: Possible contributor to blood pressure and vascular tone changes (speculative systems biology link). (Inference.)

17. Mitochondrial DNA vs nuclear DNA involvement: The report favored a recessive nuclear gene, but mitochondrial dysfunction was observed—pointing to cross-talk between nuclear and mitochondrial genomes. (Synthesis from sources.) PubMed+1

18. Photomyoclonic pathway hypersensitivity: Links retina–thalamus–motor circuitry with seizures triggered by flicker/light. (Phenotype reported; mechanism from seizure physiology.) PubMed

19. Kidney-brain-vessel triangle: Kidney failure increases vascular risk and neurotoxicity (uremic toxins), creating a vicious cycle. (General pathophysiology contextualized to this syndrome.) NCBI

20. Unknown gene with pleiotropic effect: A single gene could disrupt energy metabolism and vascular biology across organs. (Conservative conclusion given the breadth of findings.) PubMed

---

Common symptoms and signs

Because only two patients were described, the list below blends the documented features with logical clinical consequences of those features. Each item is in simple language; starred items were explicitly reported.

1. Early artery disease (atherosclerosis) — plaques in large and medium arteries much earlier than usual, affecting the aorta and arteries to the kidneys, heart, and brain. This can cause chest pain, strokes, or organ damage. Reported as diffuse and severe. Orpha

2. Bilateral sensorineural deafness* — gradual loss of inner-ear hearing. People need louder sounds and may struggle with speech clarity. PubMed

3. Diabetes mellitus* — high blood sugar due to insulin problems; symptoms include thirst, frequent urination, weight change, and infections. PubMed

4. Photomyoclonic epilepsy* — seizures or jerking triggered by flashing lights; can include brief loss of awareness or falls. PubMed

5. Progressive neurologic decline* — worsening balance, coordination, and thinking. Cerebellar signs (ataxia) can appear. NCBI

6. Kidney disease (nephropathy)* — rising creatinine, protein in urine, swelling, and blood pressure increase over time. PubMed

7. Hypertension — high blood pressure linked to kidney and vascular disease; it further speeds up vessel damage. checkorphan.org

8. Movement problems — tremor, stiffness, or myoclonus beyond light-triggered events as the nervous system deteriorates. checkorphan.org

9. Headaches or stroke-like episodes — from brain vessel disease or high blood pressure. (Consistent with severe cerebrovascular involvement.) Orpha

10. Chest pain or early heart disease — coronary atherosclerosis can cause angina or heart attacks. (Vascular domain.) Orpha

11. Leg pain with walking (claudication) — narrowed leg arteries reduce blood flow with activity. (Vascular domain.) Orpha

12. Cognitive decline — memory and thinking problems from neurodegeneration and vascular brain injury. (Neuro/vascular domains.) Orpha

13. Visual complaints during photic stimuli — flicker may provoke discomfort or jerks; seizures can include visual aura. (Seizure physiology applied to reported photomyoclonus.) PubMed

14. Fatigue and exercise intolerance — energy failure (mitochondrial dysfunction) and vascular disease limit stamina. (Mechanistic inference aligned with tissue findings.) NCBI

15. Recurrent infections/slow healing — possible with poorly controlled diabetes and kidney disease; also worsened by vascular insufficiency. (Downstream consequence.) PubMed

---

Diagnostic tests

Because the syndrome is ultra-rare with no confirmed gene, testing focuses on documented clinical features, ruling out mimics, and characterizing organ damage. The original paper and databases guide these choices.

A) Physical examination

1. Comprehensive neurologic exam — to check for myoclonus, seizures, coordination (cerebellar) signs, reflexes, and gait. This establishes the neurodegenerative component described in the syndrome. PubMed

2. Audiology-oriented bedside screening — whisper/voice tests, tuning forks, and observation of hearing aids use; formal tests follow below. (Sensorineural deafness is a core feature.) PubMed

3. Cardiovascular exam — pulses, bruits over neck/abdomen, heart sounds, leg skin changes, and walking tests to detect early, diffuse atherosclerosis. Orpha

4. Renal/edema assessment and blood pressure — look for swelling, measure BP carefully, and screen for uremic signs; high BP was noted in summaries. checkorphan.org

B) Manual/bedside tests

5. Photostimulation in a safe setting — controlled light flicker may reproduce photomyoclonus; clinicians only do this with EEG precautions. (Anchored to phenotype.) PubMed

6. Functional gait and balance scales — simple timed walking/stance tests to objectify cerebellar involvement. (Matches progressive neurologic deterioration.) NCBI

7. Ankle-brachial index (ABI) — manual Doppler or cuff measure to screen for leg artery narrowing, supporting diffuse atherosclerosis. Orpha

8. Bedside glucose checking — repeated capillary glucose helps map diabetes control pending laboratory confirmation. PubMed

C) Laboratory and pathological tests

9. Fasting plasma glucose and HbA1c — confirms diabetes and chronic control level. (Core feature.) PubMed

10. Lipid profile — evaluates cholesterol/LDL/triglycerides that may accelerate plaque formation; important given early severe atherosclerosis. Orpha

11. Kidney panel (creatinine, eGFR) and electrolytes — tracks nephropathy severity and complications. PubMed

12. Urine albumin/protein quantification — detects and follows kidney damage. PubMed

13. Mitochondrial studies in tissue (if clinically justified) — respiratory chain enzyme activity in fibroblasts/renal tissue; the original reports noted partial complex III/IV deficiency. (Highly specialized.) NCBI

14. Genetic testing panels/exome — to rule out better-defined syndromes that can mimic parts of the picture (e.g., Wolfram syndrome with diabetes and deafness; familial Danish dementia with ataxia, deafness, dementia). A causative gene for FBR itself is not known. Wikipedia+1

15. Inflammation/oxidative stress markers (research context) — not diagnostic but may be explored to understand vascular injury pathways in such a rare phenotype. (Mechanistic rationale tied to mitochondrial dysfunction.) NCBI

16. Pathology of vessels (if tissue available) — autopsy in the original cases showed diffuse atherosclerosis and arteriolosclerosis, validating the vascular burden. (Historical evidence; not routine today.) PubMed

D) Electrodiagnostic tests

17. EEG with intermittent photic stimulation — documents photomyoclonic responses/seizures and helps tailor antiseizure therapy. (Core neuro feature.) PubMed

18. Nerve conduction studies/EMG (selective) — to look for peripheral involvement or myoclonus patterns if clinically indicated; complements the neurologic exam. (Supportive, not specific.) NCBI

E) Imaging tests

19. Brain MRI — evaluates cerebellum/white matter and rules out other causes of seizures and decline; also looks for strokes from early brain atherosclerosis. (Fits neuro-vascular domains.) Orpha

20. Vascular imaging — carotid duplex or CT/MR angiography to document widespread arterial disease; coronary CT angiography or stress imaging if symptoms suggest heart involvement. (Aligns with “premature, diffuse, severe atherosclerosis.”) Orpha

Non-pharmacological treatments (therapies & others)

These are supportive strategies aligned with authoritative guidelines for cardiovascular risk reduction, diabetes self-management education, epilepsy safety, chronic kidney disease nutrition/fitness, and hearing rehabilitation. They are meant to be combined and individualized.

1. Heart-healthy eating pattern (Mediterranean/DASH principles). Emphasize vegetables, fruits, whole grains, legumes, nuts, fish; limit salt, sugar, and ultra-processed foods to lower atherosclerotic risk and blood pressure. Tie choices to diabetes and CKD needs (e.g., potassium/phosphorus limits if CKD advances). AHA Journals+2American College of Cardiology+2

2. Structured physical activity. Aim for 150–300 minutes/week of moderate-intensity aerobic activity plus muscle-strengthening work ≥2 days/week; add balance work if gait/cerebellar signs occur. Adapt to CKD/neurologic disability. PubMed

3. Therapeutic carbohydrate patterning for diabetes. Education on matching carbohydrate quantity/quality to medication and activity to improve glycemia and reduce hypoglycemia risk. American Diabetes Association+1

4. Blood-pressure self-monitoring & sodium restriction. Home BP checks and sodium ≤1.5–2.3 g/day (tailored) to slow vascular/renal damage. AHA Journals+1

5. Medical nutrition therapy for CKD. Dietitian-guided protein, sodium, potassium, and phosphorus targets; early referral improves outcomes and preparation for kidney replacement if needed. KDIGO+1

6. Smoking cessation (all forms). Eliminating tobacco/nicotine substantially lowers atherosclerotic and renal progression risk; combine behavioral support with pharmacotherapy as needed. AHA Journals

7. Hearing rehabilitation. Prompt hearing-aid fitting and communication strategies (visual cues, captioning, assistive devices) reduce isolation and improve safety. NCBI

8. Seizure self-management & photosensitivity mitigation. Blue-light filters, gradual screen brightness, avoidance of known flicker triggers, regular sleep, medication adherence, and safety planning per ILAE education resources. International League Against Epilepsy+1

9. Glycemic self-management education (DSMES). Ongoing skills-based education to optimize glucose targets, tech use (CGM), sick-day plans, and complication screening. American Diabetes Association+1

10. Falls prevention & cerebellar rehab. Physical therapy for balance, gait, and strength; home hazard reduction to lower fall risk with ataxia or postural instability. (Modeled on neuro-rehab principles used in atypical parkinsonism.) Neurosciences UCSD+1

11. Weight management. Calorie-aware, quality-focused nutrition plus activity to reach individualized targets for cardiometabolic risk reduction. AHA Journals

12. Sleep hygiene. Regular sleep timing lowers seizure risk and improves glycemia and BP; screen for sleep apnea in resistant hypertension/CKD. AHA Journals

13. Alcohol moderation/avoidance. Reduces seizure provocation, neuropathy risk, and BP/ triglycerides. AHA Journals

14. Vaccinations (general/CKD/diabetes). Stay up to date (influenza, pneumococcal, hepatitis B, etc.) to lower infection-triggered decompensation. (Diabetes/CKD guidance.) American Diabetes Association+1

15. Foot care & neuropathy prevention (diabetes). Daily checks, protective footwear, early podiatry referrals—reduces ulceration/amputation risk. American Diabetes Association

16. BP cuff and glucometer/CGM literacy. Teach calibration, technique, and data review to enable proactive adjustments. American Diabetes Association

17. Salt substitutes/potassium caution in CKD. If using salt substitutes, ensure potassium-containing products are SAFE for the patient’s kidney function. KDIGO

18. Cognitive, speech, and occupational therapy. Support for dysarthria, dysphagia, and executive deficits seen in cerebellar/degenerative disorders. PMC

19. Psychosocial support. Counseling and support groups for chronic illness burden; caregiver training and respite planning. AHA Journals

20. Advance-care planning. Early, values-based discussions about goals of care given historically poor prognosis in the index family. Genetic & Rare Diseases Center

---

Drug-treatment options

No drugs are proven to modify FBR syndrome itself. The following classes are standard-of-care for the component conditions and should be tailored to the person’s age, kidney function, comorbidities, and regional formularies. Always follow local guidelines and monitor closely.

Cardiovascular risk/atherosclerosis

1. High-intensity statins (e.g., atorvastatin, rosuvastatin) to lower LDL-C and ASCVD risk; dose per lipid profile and tolerability; monitor liver enzymes and myalgias. AHA Journals

2. Ezetimibe for additional LDL-C lowering when statins insufficient or not tolerated; minimal systemic effects. AHA Journals

3. PCSK9 inhibitors (alirocumab/evolocumab) for very high risk or familial-pattern LDL elevation; potent LDL-C reduction. AHA Journals

4. Antihypertensives with renal/cardiac benefit—ACE inhibitors/ARBs first-line when albuminuria or hypertension present; monitor potassium and creatinine. KDIGO

5. Antiplatelet therapy (aspirin) only when indicated by ASCVD risk/secondary prevention—not for routine primary prevention in low risk; assess bleeding risk. AHA Journals

Diabetes

6. Metformin (if eGFR allows) for glycemic control and weight neutrality; review renal thresholds and GI tolerance. American Diabetes Association

7. SGLT2 inhibitors (e.g., empagliflozin/dapagliflozin) for renal and cardiovascular protection in T2D with CKD or high CV risk; watch for mycotic infections, volume depletion, and eGFR cutoffs. American Diabetes Association+1

8. GLP-1 receptor agonists (e.g., semaglutide) for potent A1C lowering, weight loss, and CV benefit; titrate slowly for GI effects. American Diabetes Association

9. Basal/bolus insulin when hyperglycemia is severe, during illness, or if oral/GLP-1/SGLT2 are inadequate/contraindicated; provide hypoglycemia education. American Diabetes Association

Kidney disease

10. Finerenone (in T2D with CKD and albuminuria) to reduce CKD progression and CV events; monitor potassium and eGFR. KDIGO

11. Phosphate binders / vitamin D analogs if CKD-MBD emerges; guided by labs and KDIGO mineral-bone targets. KDIGO

Epilepsy (photomyoclonic seizures)

12. Valproate—broad-spectrum antiseizure with strong anti-myoclonic effect; avoid in pregnancy; monitor LFTs, platelets, weight. Follow ILAE guidance on selection. International League Against Epilepsy

13. Levetiracetam—effective for myoclonic/generalized seizures; favorable interaction profile; watch mood/irritability. International League Against Epilepsy

14. Clonazepam—benzodiazepine with anti-myoclonic activity; sedation/tolerance risks; often as adjunct. International League Against Epilepsy

15. Lamotrigine—useful across generalized seizures; titrate slowly to minimize rash risk; may worsen myoclonus in some—monitor. International League Against Epilepsy

Hearing loss & symptom support

16. Hearing-aid fittings (device prescription, not a drug) often paired with intranasal steroids if concurrent Eustachian inflammation (case-by-case). Evidence base pertains to sensorineural hearing rehabilitation. NCBI

17. Statin/ACEI overlap also indirectly supports cochlear microvasculature via vascular risk reduction (inference from CV guidelines). AHA Journals

Additional cardiometabolic agents (individualized)

18. Eicosapentaenoic acid ethyl (icosapent) for hypertriglyceridemia in high-risk patients already on statins; outcome benefit in selected groups. AHA Journals

19. Beta-blockers/CCBs when angina or rate control is needed (patient-specific). AHA Journals

20. Diuretics for BP/volume management in CKD/heart involvement; watch electrolytes and renal function. KDIGO

Doses, timing, and sequencing depend on age, renal function (eGFR), comorbidities, drug interactions, and local protocols. Use ADA/KDIGO/AHA/ILAE guidance for specifics. International League Against Epilepsy+3American Diabetes Association+3KDIGO+3

---

Dietary molecular supplements

Because FBR has no supplement-based evidence, choices should target general cardiometabolic, neurologic, and renal health. Avoid high-potassium/phosphorus products in CKD and beware drug–supplement interactions.

1. Omega-3 (EPA/DHA). May lower triglycerides and systemic inflammation; prescription EPA has outcome data in high-risk hypertriglyceridemia when added to statins. Dose and purity matter; monitor for bleeding with antiplatelets. AHA Journals

2. Vitamin D (correct deficiency). Supports bone/mineral targets in CKD and general health; dose per level and KDIGO guidance. KDIGO

3. Folate/B-complex (correct deficiency). Addresses neuropathy/anemia risks; avoid excess in CKD without indication. KDIGO

4. Coenzyme Q10 (adjunct in statin myalgia/mitochondrial hypotheses). Evidence is mixed; consider trial if myalgias occur. AHA Journals

5. Magnesium (only if low and CKD allows). Low magnesium may worsen arrhythmia/muscle issues; check levels and adjust for eGFR. KDIGO

6. Fiber (psyllium/inulin) to improve glycemia and lipids and support bowel health; introduce gradually to avoid bloating. American Diabetes Association

7. Protein supplementation (renal-appropriate) for sarcopenia with supervised targets—avoid excess in advanced CKD. KDIGO

8. Thiamine replacement if deficiency risk (diuretics, malnutrition); supports neurologic function. KDIGO

9. Probiotics (adjunct for GI tolerance with metformin/antibiotics); evidence variable; safe in most but not for immunocompromised without advice. American Diabetes Association

10. Antioxidant-rich whole foods (berries, leafy greens, olive oil, nuts) preferred over pills for vascular benefit. AHA Journals

---

Immunity-booster / regenerative / stem-cell drugs

There is no evidence that immune-boosting or stem-cell drugs repair FBR syndrome. In advanced CKD, kidney transplantation (a surgery, not a drug) may be indicated based on standard criteria. The agents below are supportive in mainstream indications—they are not FBR cures:

1. Erythropoiesis-stimulating agents (ESAs) in CKD anemia when indicated—improve hemoglobin and quality of life; dose guided by hemoglobin and iron status. KDIGO

2. IV iron for CKD anemia with iron deficiency—repletes iron stores and reduces ESA needs; monitor for reactions and iron indices. KDIGO

3. Vaccines (influenza, pneumococcal, hepatitis B)—train immune system to prevent infections that can destabilize CKD/diabetes/epilepsy. American Diabetes Association+1

4. SGLT2 inhibitors (renal- and cardio-protective in T2D/CKD) reduce inflammation/fibrosis pathways in kidneys/heart; not “regenerative,” but disease-modifying for those indications. KDIGO

5. GLP-1 receptor agonists reduce weight/inflammation markers and CV risk in T2D; again, not immune boosters, but risk-modifying. American Diabetes Association

6. Vitamin D analogs in CKD-MBD—support bone/immune interfaces; use per labs; not curative for FBR. KDIGO

---

Surgeries/procedures

1. Coronary/vascular revascularization (PCI/CABG, carotid/renal interventions) when symptomatic or high-risk stenoses exist—restores blood flow and treats consequences of premature atherosclerosis. Decision is individualized by heart/vascular teams. AHA Journals

2. Implantable devices for hearing (cochlear implant) when severe bilateral sensorineural loss persists despite hearing aids—improves speech perception and safety. NCBI

3. Renal replacement therapy (hemodialysis/peritoneal dialysis) when kidney failure occurs—maintains solute and fluid balance while evaluating candidacy for transplant. KDIGO

4. Kidney transplantation for eligible patients—restores renal function and quality of life; requires lifelong immunosuppression and careful cardiovascular/neurologic evaluation. KDIGO

5. Epilepsy device/surgical options (e.g., VNS, selected epilepsy surgeries) in refractory cases after comprehensive evaluation; data are for generalized/myoclonic epilepsy broadly, not specifically FBR. International League Against Epilepsy

---

Preventions

1. No tobacco exposure (primary and second-hand). AHA Journals

2. Maintain healthy diet pattern (Mediterranean/DASH). AHA Journals

3. Meet WHO activity targets weekly. PubMed

4. Achieve BP, A1C, and lipid targets per guidelines. American Diabetes Association+1

5. Routine vaccinations to prevent destabilizing infections. American Diabetes Association

6. Regular CKD and diabetes screening (albuminuria, eGFR, retinopathy, neuropathy). American Diabetes Association+1

7. Seizure-trigger avoidance and medication adherence. International League Against Epilepsy

8. Hearing conservation (noise protection, prompt otology care). NCBI

9. Healthy weight and sleep. AHA Journals

10. Early referral to specialists (cardiology, nephrology, neurology, audiology, endocrinology) for coordinated, proactive care. KDIGO

---

When to see doctors

• Chest pain, shortness of breath, sudden weakness, speech or vision changes—possible heart attack or stroke: emergency care now. AHA Journals

• New or worsening seizures, confusion after lights/screens, or falls—urgent neurology review. International League Against Epilepsy

• Sudden hearing drop or persistent ringing—prompt audiology/ENT evaluation improves outcomes. NCBI

• Swelling, reduced urine, rising blood pressure, or lab changes—nephrology review to prevent kidney decline. KDIGO

• Very high or very low blood sugar, vomiting, dehydration, or recurrent hypoglycemia—immediate diabetes care. American Diabetes Association

---

What to eat / what to avoid

1. Build plates around plants (vegetables, fruits, legumes, whole grains), olive oil, nuts, and fish; portion whole-grain starches alongside protein and fiber to steady glucose. AHA Journals

2. Choose lean proteins (fish, poultry, legumes); tailor protein for CKD stage with a renal dietitian. KDIGO

3. Limit sodium—prefer herbs, spices, lemon; check labels. American College of Cardiology

4. Prefer water/unsweetened drinks; avoid sugar-sweetened beverages to help weight, BP, and A1C. American Diabetes Association

5. Use high-fiber carbs (oats, barley, legumes) to aid lipids and glucose. American Diabetes Association

6. If CKD progresses, adjust potassium/phosphorus (bananas, oranges, colas, processed meats) per labs. KDIGO

7. Limit ultra-processed foods (fast food, packaged snacks, deli meats). AHA Journals

8. Moderate alcohol or avoid if seizures or poor control. AHA Journals

9. Mindful portions—use smaller plates, slow eating, and consistent mealtimes. AHA Journals

10. Work with a dietitian for a personalized plan that integrates diabetes, CKD, and cardiovascular goals. KDIGO

---

Frequently asked questions

1) Is FBR syndrome definitely genetic?
Likely yes, but the causing gene is unknown; only a single family has been described, so inheritance remains presumptive. Genetic & Rare Diseases Center

2) Is there a cure?
No disease-specific cure exists; care focuses on treating each problem (vessels, kidneys, diabetes, seizures, hearing). Genetic & Rare Diseases Center

3) Is it mitochondrial disease?
A partial complex III/IV defect was reported in kidney/fibroblasts, suggesting a mitochondrial angle, but this is not definitive. Genetic & Rare Diseases Center

4) How is it diagnosed today?
By clinical features plus exclusion of more common causes; modern teams would use genomic panels/exome to search for candidate variants, but no specific gene has been linked yet. (Inference based on current rare-disease practice; primary descriptions predated routine exome.) Genetic & Rare Diseases Center

5) What is the expected course?
In the index family, progression led to early adult death due to vascular/neuro/renal complications; actual variability is unknown due to the absence of further cases. Genetic & Rare Diseases Center

6) Which specialists should be involved?
Cardiology, nephrology, neurology/epileptology, endocrinology/diabetes education, audiology/ENT, rehabilitation—coordinated care is essential. KDIGO+2American Diabetes Association+2

7) Are statins/SGLT2/GLP-1 drugs appropriate?
If the person meets standard indications (lipids, CKD/T2D, CV risk), yes—based on mainstream guidelines, not because of FBR per se. AHA Journals+2KDIGO+2

8) Can photosensitivity seizures be prevented?
Triggers can often be reduced (screen brightness, blue-light filters, avoiding flicker, sleep regularity) plus appropriate antiseizure medication. International League Against Epilepsy

9) Could cochlear implants help?
For severe bilateral sensorineural loss unhelped by hearing aids, cochlear implants can improve speech understanding. NCBI

10) Is kidney transplantation an option?
Yes, if standard eligibility criteria are met; risks/benefits require evaluation by a transplant center. KDIGO

11) What diet is “best”?
Use a Mediterranean/DASH-style pattern, personalized for diabetes and CKD labs. AHA Journals+1

12) Are there research trials?
None specific to FBR are listed in modern summaries; searching by its alternate names is reasonable, but the syndrome is not currently an active trial area. (Based on lack of recent literature; Orphanet/GARD note no new descriptions since 1994.) Genetic & Rare Diseases Center+1

13) What monitoring is key?
BP, A1C/CGM data, lipids, kidney labs (eGFR, albuminuria), seizure control, hearing tests, and cardiovascular symptom review. American Diabetes Association+1

14) Can lifestyle changes really help?
Yes—diet, activity, tobacco abstinence, and weight management reduce cardio-renal risk and support glycemic and seizure control. AHA Journals+1

15) Where can I read more?
See the GARD and Orphanet entries, plus MedGen for clinical descriptors. Genetic & Rare Diseases Center+2Orpha+2

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 25, 2025.